Chemotherapy-induced nausea and vomiting (CINV) is a major reason for readmissions to the hospital post chemotherapy, according to James Natale, PharmD, BCOP. The use of standard protocols, along with electronic medical records, helps to reduce the rate of readmissions and improve outcomes.
There are various quality-related fee-for-performance guidelines being implemented that are related to the prevention of CINV, says Natale. The use of combination products that target multiple mechanisms in CINV prevention can offer an added convenience, he says, as well as help with oral chemotherapy medication adherence.
Any cost calculations associated with CINV management should take into consideration the efficacy of the antiemetic agent, explains Natale. The total cost of care for CINV increases if there is a lot of breakthrough nausea and vomiting, which may lead to the need for intravenous fluids and/or additional antiemetics. One of the best ways to reduce overall costs is to prevent CINV from ever occurring, adds Natale. Also, it is important to consider the patient cost. It is preferable to choose the most effective, as well as cost-effective agent.